FDA Draws Regulatory Line Between Moxduo, HIV Combos
Executive Summary
HIV products often increase potency in combination, agency says.
You may also be interested in...
Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J
Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.
FDA “Combination Rule” Trips Up QRxPharma’s Moxduo
Morphine/oxycodone fixed-dose product must offer efficacy or safety advantage over individual drug components because the two opioids are not generally used together to treat acute pain, agency says; QRxPharma fails to convince advisory committee that respiratory safety advantage exists.
QRxPharma Given Statistical Leeway With Moxduo, To No Avail
In search of evidence of a respiratory safety benefit with the two-opioid combination product, FDA agreed to consider exploratory and post hoc analyses from a safety study that failed its primary endpoint.